UNDERSTANDING
They not only generate energy but also play an important role in cell proliferation, signaling, etc.
Mitochondria have unique characteristics that can be delivered into cells through endocytosis. With PAEAN's mitochondria-based therapeutics, we transform mitochondria into powerful biopharmaceutical agents to address critical medical needs.
MitoTherapy Products are novel medicinal products using mitochondria isolated from human stem cells or human blood. Mitochondria are unique organelles that are responsible for energy production in cells. Based on our experimental results, mitochondria have a high potential to treat inflammatory diseases.
PAEAN's proprietary platform technology facilitates the engineering of modified mitochondria capable of delivering therapeutic agents to designated cellular targets. This innovative technology integrates mitochondria with single-chain variable fragments of antibodies specifically designed to interact with target cells (called as CAR-Mito). Additionally, there is the capability to conjugate anti-cancer agents or chemical payloads to these modified mitochondria, thereby enhancing their efficacy in selectively targeting and killing cancer cells (called as AMDC).
Mitochondria-augmented Cell Therapy represents a paradigm shift in regenerative medicine, designed to overcome the metabolic limitations of traditional autologous cell treatments. By isolating a patient’s own stem or immune cells and enriching them with healthy, functional mitochondria, the technology actively restores cellular bioenergetic capacity. This process transforms standard biological material into metabolically optimized therapeutic agents, ensuring that the cells reintroduced to the body possess superior viability, potency, and the energy required to maximize clinical efficacy
PAEAN’s Pipeline reflects our strategic focus on high-burden diseases with limited treatment options, progressing toward regulatory milestones with the support of national and global funding partners.
| Platform | Indication | Drug Discovery | Pre-Clinical | IND | Phase 1 | Phase 2 | |
|---|---|---|---|---|---|---|---|
| PN-101 Mitochondrial Transplantation (MitoTherapy Product) | PM/DM | | |||||
| Parkinson Disease | | ||||||
| Hearing Loss | | ||||||
| Ophthalmic Disease | | ||||||
| PN-30X Modified Mitochondrial Transplantation (MitoCeutical Product) | Cancer, CNS Diseases | | |||||
| Mitochondrial Augmentation Cell Therapy (Mitoaugmentation Product) | TBD | | |||||
